Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 17, 2007

Vernalis and Servier Research Group Ink Discovery Deal

  • Vernalis and Servier entered into a joint, three-year, oncology drug discovery collaboration. Under the terms of the collaboration, which utilizes Vernalis' drug discovery platform on an undisclosed target, Vernalis will receive an upfront payment and a share in the downstream success of the product.

    "The partnership with Vernalis is a major step in our strategy to increase our efforts in the development of novel anti-cancer therapeutic approaches," remarks Emmanuel Canet, M.D., Ph.D., vp Servier R&D. “This collaboration will expedite the discovery of innovative compounds with potential use in therapeutic indications with high unmet medical need.”



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »